Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability o…

Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued ...
Oncology Nurse Advisor

IMPT Delivers Superior OS, Less High-Grade Toxicity in Oropharyngeal Cancer

Intensity-modulated proton therapy (IMPT) improves overall survival (OS) and reduces high-grade toxicity compared with intensity-modulated radiation ...

Benitec Biopharma Inc.: Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy a…

Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued ...
Targeted Oncology

Biomarkers, Risk, and Trials: De-escalation vs Intensification in HNSCC

HPV status, particularly combined p16 and HPV positivity, is vital for patient selection in de-escalation strategies for ...

Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...
Targeted Oncology

FDA Orphan Drug Designation Given to NP-G2-044 in Pancreatic Cancer

NP-G2-044 (Prilukae), a novel oral fascin inhibitor, has earned orphan drug designation (ODD) from the FDA for the treatment ...
Healthcare in Europe

Proton therapy shows survival benefit for patients with head and neck cancers

Study represents the largest randomized Phase III trial comparing proton to traditional radiation with photons for ...
Le Lézard

Naveris® to Highlight New Publications at the 44th Annual J.P. Morgan Healthcare Conference

Naveris, Inc., the leader in precision oncology diagnostics for viral-driven cancers, today announced that it will be ...